APA (7th ed.) Citation

Kempsford, R., Norris, V., & Siederer, S. (2013). Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulmonary pharmacology & therapeutics, 26(2), 256-264. https://doi.org/10.1016/j.pupt.2012.12.001

Chicago Style (17th ed.) Citation

Kempsford, Rodger, Virginia Norris, and Sarah Siederer. "Vilanterol Trifenatate, a Novel Inhaled Long-acting Beta2 Adrenoceptor Agonist, Is well Tolerated in Healthy Subjects and Demonstrates Prolonged Bronchodilation in Subjects with Asthma and COPD." Pulmonary Pharmacology & Therapeutics 26, no. 2 (2013): 256-264. https://doi.org/10.1016/j.pupt.2012.12.001.

MLA (9th ed.) Citation

Kempsford, Rodger, et al. "Vilanterol Trifenatate, a Novel Inhaled Long-acting Beta2 Adrenoceptor Agonist, Is well Tolerated in Healthy Subjects and Demonstrates Prolonged Bronchodilation in Subjects with Asthma and COPD." Pulmonary Pharmacology & Therapeutics, vol. 26, no. 2, 2013, pp. 256-264, https://doi.org/10.1016/j.pupt.2012.12.001.